Grifols Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Grifols kazanç ve gelirin sırasıyla yıllık 28.6% ve 6.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 30.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 9.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

28.6%

Kazanç büyüme oranı

30.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	36.4%
Gelir büyüme oranı	6.1%
Gelecekteki özkaynak getirisi	9.3%
Analist kapsamı	Good
Son güncelleme	30 Oct 2024

Gelecekteki son büyüme güncellemeleri

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Recent updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

Kazanç ve Gelir Büyüme Tahminleri

BME:GRF - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	8,119	735	870	1,146	12
12/31/2025	7,594	605	673	940	14
12/31/2024	7,103	368	321	686	14
6/30/2024	6,811	166	77	377	N/A
3/31/2024	6,656	189	-187	105	N/A
12/31/2023	6,592	59	-87	208	N/A
9/30/2023	6,535	23	-217	119	N/A
6/30/2023	6,479	-5	-496	-123	N/A
3/31/2023	6,358	47	-485	-107	N/A
12/31/2022	6,064	208	-386	-11	N/A
9/30/2022	5,549	149	-272	50	N/A
6/30/2022	5,207	66	-36	289	N/A
3/31/2022	5,016	112	137	454	N/A
12/31/2021	4,933	189	282	597	N/A
9/30/2021	5,044	361	400	727	N/A
6/30/2021	5,199	667	597	909	N/A
3/31/2021	5,231	562	847	1,183	N/A
12/31/2020	5,340	619	748	1,110	N/A
9/30/2020	5,392	687	663	1,081	N/A
6/30/2020	5,353	557	551	964	N/A
3/31/2020	5,235	697	425	842	N/A
12/31/2019	5,099	625	157	569	N/A
9/30/2019	4,961	552	309	668	N/A
6/30/2019	4,790	565	275	634	N/A
3/31/2019	4,620	568	147	477	N/A
12/31/2018	4,487	597	430	737	N/A
9/30/2018	4,332	699	365	680	N/A
6/30/2018	4,246	704	405	712	N/A
3/31/2018	4,279	672	N/A	789	N/A
12/31/2017	4,318	663	N/A	842	N/A
9/30/2017	4,348	571	N/A	751	N/A
6/30/2017	4,291	559	N/A	765	N/A
3/31/2017	4,153	554	N/A	640	N/A
12/31/2016	4,050	545	N/A	553	N/A
9/30/2016	4,014	537	N/A	683	N/A
6/30/2016	3,986	535	N/A	652	N/A
3/31/2016	3,985	529	N/A	767	N/A
12/31/2015	3,935	532	N/A	743	N/A
9/30/2015	3,789	533	N/A	755	N/A
6/30/2015	3,645	507	N/A	836	N/A
3/31/2015	3,466	478	N/A	888	N/A
12/31/2014	3,355	470	N/A	979	N/A
9/30/2014	3,133	417	N/A	882	N/A
6/30/2014	2,972	388	N/A	712	N/A
3/31/2014	2,856	376	N/A	625	N/A
12/31/2013	2,742	346	N/A	592	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: GRF 'nin tahmini kazanç büyümesi (yıllık 28.6% ) tasarruf oranının ( 1.7% ) üzerindedir.

Kazançlar ve Piyasa: GRF şirketinin kazançlarının (yıllık 28.6% ) Spanish pazarından (yıllık 8.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: GRF şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: GRF şirketinin gelirinin (yıllık 6.1% ) Spanish pazarından (yıllık 5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: GRF şirketinin gelirinin (yıllık 6.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: GRF 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 9.3 %).

Grifols Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Price target decreased by 7.1% to €17.40

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 14%

Recent updates

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings: EPS misses analyst expectations

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Investor sentiment deteriorates as stock falls 16%

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

New minor risk - Earnings quality

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin